Literature DB >> 16712897

Production and characterization of vaccines based on flaviviruses defective in replication.

Peter W Mason1, Alexandr V Shustov, Ilya Frolov.   

Abstract

To develop new vaccine candidates for flavivirus infections, we have engineered two flaviviruses, yellow fever virus (YFV) and West Nile virus (WNV), that are deficient in replication. These defective pseudoinfectious viruses (PIVs) lack a functional copy of the capsid (C) gene in their genomes and are incapable of causing spreading infection upon infection of cells both in vivo and in vitro. However, they produce extracellular E protein in form of secreted subviral particles (SVPs) that are known to be an effective immunogen. PIVs can be efficiently propagated in trans-complementing cell lines making high levels of C or all three viral structural proteins. PIVs derived from YFV and WNV, demonstrated very high safety and immunization produced high levels of neutralizing antibodies and protective immune response. Such defective flaviviruses can be produced in large scale under low biocontainment conditions and should be useful for diagnostic or vaccine applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16712897      PMCID: PMC2430078          DOI: 10.1016/j.virol.2006.04.003

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  45 in total

1.  A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.

Authors:  T J Kochel; K Raviprakash; C G Hayes; D M Watts; K L Russell; A S Gozalo; I A Phillips; D F Ewing; G S Murphy; K R Porter
Journal:  Vaccine       Date:  2000-07-15       Impact factor: 3.641

2.  Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.

Authors:  N Kanesa-thasan; J J Smucny; C H Hoke; D H Marks; E Konishi; I Kurane; D B Tang; D W Vaughn; P W Mason; R E Shope
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

3.  Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

Authors:  Thomas P Monath; Karen McCarthy; Philip Bedford; Casey T Johnson; Richard Nichols; Sutee Yoksan; Ron Marchesani; Michael Knauber; Keith H Wells; Juan Arroyo; Farshad Guirakhoo
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

4.  Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.

Authors:  E Konishi; M Yamaoka; I Kurane; P W Mason
Journal:  Virology       Date:  2000-03-01       Impact factor: 3.616

5.  Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines.

Authors:  Rafik Fayzulin; Frank Scholle; Olga Petrakova; Ilya Frolov; Peter W Mason
Journal:  Virology       Date:  2006-05-02       Impact factor: 3.616

6.  Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles.

Authors:  E Konishi; A Fujii; P W Mason
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms.

Authors:  J H Aberle; S W Aberle; S L Allison; K Stiasny; M Ecker; C W Mandl; R Berger; F X Heinz
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

8.  West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.

Authors:  B S Davis; G J Chang; B Cropp; J T Roehrig; D A Martin; C J Mitchell; R Bowen; M L Bunning
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis.

Authors:  S Y Xiao; H Guzman; H Zhang; A P Travassos da Rosa; R B Tesh
Journal:  Emerg Infect Dis       Date:  2001 Jul-Aug       Impact factor: 6.883

10.  A 'minimal' approach in design of flavivirus infectious DNA.

Authors:  V P Mishin; F Cominelli; V F Yamshchikov
Journal:  Virus Res       Date:  2001-12-04       Impact factor: 3.303

View more
  41 in total

1.  Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis.

Authors:  Nicholas O Fischer; Ernesto Infante; Tomohiro Ishikawa; Craig D Blanchette; Nigel Bourne; Paul D Hoeprich; Peter W Mason
Journal:  Bioconjug Chem       Date:  2010-06-16       Impact factor: 4.774

2.  Helices alpha2 and alpha3 of West Nile virus capsid protein are dispensable for assembly of infectious virions.

Authors:  Petra Schlick; Christian Taucher; Beate Schittl; Janina L Tran; Regina M Kofler; Wolfgang Schueler; Alexander von Gabain; Andreas Meinke; Christian W Mandl
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

3.  The amino-terminal domain of alphavirus capsid protein is dispensable for viral particle assembly but regulates RNA encapsidation through cooperative functions of its subdomains.

Authors:  Valeria Lulla; Dal Young Kim; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

4.  West Nile virus genome with glycosylated envelope protein and deletion of alpha helices 1, 2, and 4 in the capsid protein is noninfectious and efficiently secretes subviral particles.

Authors:  Justin A Roby; Roy A Hall; Alexander A Khromykh
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

5.  Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach.

Authors:  Chao Shan; Xuping Xie; Jing Zou; Roland Züst; Bo Zhang; Rebecca Ambrose; Jason Mackenzie; Katja Fink; Pei-Yong Shi
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

6.  Trans Complementation of Replication-defective Omsk Hemorrhagic Fever Virus for Antiviral Study.

Authors:  Qiuyan Zhang; Na Li; Chenglin Deng; Zherui Zhang; Xiaodan Li; Kentaro Yoshii; Hanqing Ye; Bo Zhang
Journal:  Virol Sin       Date:  2019-04-04       Impact factor: 4.327

7.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Production of pseudoinfectious yellow fever virus with a two-component genome.

Authors:  Alexandr V Shustov; Peter W Mason; Ilya Frolov
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2.

Authors:  Ryosuke Suzuki; Evandro R Winkelmann; Peter W Mason
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation.

Authors:  Svetlana Atasheva; Dal Young Kim; Maryna Akhrymuk; David G Morgan; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.